Cancer News
OncoLink Cancer News - HealthDay


Azacitidine May Be Effective in Myelodysplastic Syndrome

-- Lisa Cockrell, PhD

Monday, February 23, 2009

MONDAY, Feb. 23 (HealthDay News) -- Azacitidine, as opposed to conventional care, improves overall survival in patients with higher-risk myelodysplastic syndrome, according to research published online Feb. 19 in The Lancet Oncology.

Pierre Fenaux, M.D., of the Universite Paris XIII in France, and colleagues conducted a phase III international open-label trial of 358 patients with higher-risk myelodysplastic syndrome. Patients were randomized to receive either azacitidine or conventional care consisting of best supportive care, low-dose cytarabine or intensive chemotherapy. A median follow-up of 21.1 months was reported.

Median overall survival was significantly lengthened in the azacitidine group compared with conventional care (24.5 months versus 15 months), the investigators found. After two years, 50.8 percent of patients in the azacitidine group were alive compared with 26.2 percent in the conventional care group. Patients in both groups reported grade 3 or 4 peripheral cytopenias as the most common adverse event, the researchers report.

"The results of this study indicate that azacitidine significantly lengthens overall survival and changes the natural history of myelodysplastic syndrome in patients with higher-risk disease," the authors state, but add "intensive chemotherapy may remain the appropriate treatment in some situations in higher-risk myelodysplastic syndrome, especially before allogeneic stem-cell transplantation in candidates for this procedure who have an excess of marrow blasts."

Several of the study authors report financial relationships with pharmaceutical companies, including Celgene, which sponsored the research.

Abstract
Full Text (subscription or payment may be required)

Specialties Cardiology
Diabetes & Endocrinology
Internal Medicine
Family Practice

Copyright © 2009 ScoutNews, LLC. All rights reserved.


I Wish You Knew

Nutrition During Cancer Treatment

View More



Blogs and Web Chats

OncoLink Blogs give our readers a chance to react to and comment on key cancer news topics and provides a forum for OncoLink Experts and readers to share opinions and learn from each other.




OncoLink OncoPilot

Facing a new cancer diagnosis or changing the course of your current treatment? Let our cancer nurses help you through!

Learn More